Ketorolac in Palatoplasty
Ketorolac in Palatoplasty: A Randomized Blinded Controlled Trial.
The University of Texas Health Science Center, Houston
74 participants
Sep 17, 2021
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to see if the addition of IV Ketorolac to usual care multi-modal pain therapy compared to usual care will improve oral intake post-operatively
Eligibility
Inclusion Criteria1
- Patient with Cleft palate (Complete and incomplete), with or without cleft lip, unilateral or bilateral
Exclusion Criteria8
- Syndromic Cleft Palate patients
- Previous palatoplasty
- Major unrepaired cardiac malformation
- History of GI complications (GI Bleed, Gastric Ulceration)
- History of Renal disorder
- History of coagulopathy (As contraindication to NSAID use)
- Feeding tube dependency
- Patients whose parents refuse to consent to randomization
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04771156